A gentler treatment for children whose leukemia has come back could boost survival and quality of life, a study led by a UCL academic has found.
Doctors have found a gentler treatment for children whose leukaemia has come back, which could boost survival and quality of ...
Presentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate ...
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
One Kansas City child is battling cancer and a broken femur, but he isn't alone.
Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial. The Food and Drug Administration (FDA) ...
The ORR was 69% (95% CI, 61-76) in the zanubrutinib arm and 46% (95% CI, 34-58) in the obinutuzumab monotherapy arm. The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results